As a network of the National Competent Authorities (NCAs) in the EU, the HMA is cooperating together with EMA and the European Commission to fight the outbreak of the novel coronavirus disease (COVID-19).

All the COVID-19 related information, guidelines and other documents relevant to the European Medicines Regulatory Network can be found here.

HMA Calendar

No events

2024	Belguim
2023	Spain
2023	Sweden
2022	Czech Republic
2022	France
2021	Slovenia
2021	Portugal

The United Kingdom submitted on 29 March 2017 the notification of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union. This means that unless a ratified withdrawal agreement establishes another date, all Union primary and secondary law ceases to apply to the United Kingdom from the UK withdrawal date. The United Kingdom will then become a 'third country'.

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

For centrally authorised products please find guidance by the European Medicines Agency and European Commission here.
For questions & answers on EU actions to prevent medicine shortages due to Brexit please find the information prepared by the European Medicines Agency here.

For products authorised in decentralised or mutual recognition procedures please find guidance by CMDh here and CMDv here.
For information to sponsors of clinical trials regarding continuous compliance with the EU legislation following Brexit please find the joint technical notice by the European Commission, EMA and HMA here.
For country specific issues please revert to the NCA in that country.
The Heads of Medicines Agencies would like to reiterate the paramount importance for all involved to prepare for withdrawal in the interest European human and animal health.